Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (0)

Novo Says Early Use of Victoza Aids Type 2 Control


Oct 2, 2011

Victoza was introduced into the U.S. market in early 2010

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.)

In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.

Typically, newly diagnosed type 2s begin with a single drug to control their blood glucose-usually a sulfonylurea or metformin. Both types of drugs are inexpensive and have been staples of the diabetes drug arsenal for decades. (Sulfonylureas increase insulin production. Metformin suppresses glucose production in the liver.)

Victoza, an injectible drug approved for US sale in early 2010, is a long-acting glucagon-like peptide (GLP-1) analog that stimulates increased insulin production when blood glucose levels are higher than normal. Unlike its naturally occurring counterpart, the drug remains stable for hours at a time, which means that it can be delivered on a once-daily basis. The drug's other beneficial effects include greater appetite suppression and body weight maintenance capability than sulfonylureas, as well as the ability to lower triglyceride levels.

The 26-week Novo study looked at type 2 patients who either had previously received no drugs or were taking only one oral diabetes drug daily. It found that 72 percent of patients treated early with a combination of Victoza and an oral agent achieved the European-recommended A1C target of less than 7%. (The American Diabetes Association's recommended target is 7%.) This compared to 49 percent of subjects who achieved the recommended A1C levels when they waited until later in the progression of their diabetes to begin taking the combination therapy.


Categories: A1C, American Diabetes Association, Blood Glucose, Combination Therapy for Type 2 Diabetes, Diabetes, Diabetes, European Association for the Study of Diabetes, GLP-1, Januvia/Janumet, Liraglutide, Metformin, Novo Nordisk, Sulfonylureas, Triglycerides, Type 2 Diabetes, Type 2 Issues, Victoza



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.